Financialsexperimental
BRISTOL MYERS SQUIBB CO (CELG-RI). Every figure is as filed in the company's 10-Q and 10-K reports. Quarters a filing does not report on their own are worked out from its year-to-date figures and marked *.
USD in millions
| Cash Flow | FY FY25 31 Dec 2025 | FY FY24 31 Dec 2024 | FY FY23 31 Dec 2023 | FY FY22 31 Dec 2022 | FY FY21 31 Dec 2021 |
|---|---|---|---|---|---|
| Net earnings/(loss) | 7,055 | -8,933 | 8,040 | 6,345 | 7,014 |
| Depreciation and amortization, net | 4,011 | 9,600 | 9,760 | 10,276 | 10,686 |
| Deferred income taxes | -965 | -2,089 | -3,288 | -2,738 | -1,393 |
| Stock-based compensation | 553 | 507 | 518 | 457 | 583 |
| Impairment charges | 1,098 | 2,963 | 255 | 179 | 1,207 |
| Divestiture gains and royalties | -684 | ||||
| Pension settlements and amortization | 35 | ||||
| Divestiture gains and royalties | -1,165 | -1,119 | -884 | -1,063 | |
| Acquired IPRD | 815 | 1,157 | |||
| Acquired IPRD | 3,721 | 13,373 | 913 | ||
| IPRD charge - MyoKardia acquisition | 0 | ||||
| Equity investment (gains)/losses, net | -280 | -16 | 160 | 801 | -745 |
| Contingent consideration fair value adjustments | 351 | -8 | -9 | -542 | |
| Other adjustments | 232 | 94 | 308 | 232 | 142 |
| Receivables | -295 | 264 | -995 | -663 | -1,054 |
| Inventories | -184 | -486 | -751 | -69 | 13 |
| Accounts payable | -2 | 184 | 198 | 109 | 245 |
| Rebates and discounts | -441 | 1,484 | 904 | 427 | 863 |
| Income taxes payable | -4 | -1,260 | -603 | -1,423 | -1,063 |
| Other | 471 | 624 | -667 | -610 | -257 |
| Net cash provided by operating activities | 14,156 | 15,190 | 13,860 | 13,066 | 16,207 |
| Sale and maturities of marketable debt securities | 1,975 | 1,122 | 733 | 6,411 | 4,196 |
| Purchase of marketable debt securities | -2,000 | -769 | -1,774 | -3,592 | -5,478 |
| Proceeds from sales of equity investment securities | 218 | 2,579 | |||
| Proceeds from sales of equity investments | 77 | 265 | 215 | ||
| Capital expenditures | -1,311 | -1,248 | -1,209 | -1,118 | -973 |
| Divestiture and other proceeds | 748 | ||||
| Divestiture and other proceeds | 1,071 | 1,099 | 909 | 1,305 | |
| Acquisition and other payments, net of cash acquired | -3,944 | -21,821 | -1,169 | -4,286 | -1,610 |
| Net cash provided by/(used in) investing activities | -4,132 | -21,352 | -2,295 | -1,062 | -538 |
| Short-term debt obligations, net | -120 | 194 | -160 | ||
| Proceeds from issuance of short-term debt obligations | 0 | 2,987 | |||
| Other short-term financing obligations, net | 25 | 99 | |||
| Repayments of long-term debt | -10,940 | -2,873 | -3,879 | -11,431 | -6,022 |
| Repayments of short-term debt obligations | 0 | 3,000 | |||
| Dividends | -5,045 | -4,863 | -4,744 | -4,634 | -4,396 |
| Proceeds from issuance of long-term debt | 5,740 | 12,883 | 4,455 | 5,926 | 0 |
| Stock option proceeds and other, net | -128 | -106 | |||
| Net cash provided by/(used in) financing activities | -10,348 | 5,127 | -9,416 | -16,962 | -16,224 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | 195 | -137 | 45 | -33 | -102 |
| Repurchase of common stock | 0 | 0 | 5,155 | 8,001 | 6,287 |
| Stock option proceeds and other, net | 27 | 984 | 641 | ||
| Increase/(decrease) in cash, cash equivalents and restricted cash | -129 | -1,172 | 2,194 | -4,991 | -657 |
| Cash, cash equivalents and restricted cash at beginning of period | 10,347 | 11,519 | 9,325 | 14,316 | 14,973 |
| Cash, cash equivalents and restricted cash at end of period | 10,218 | 10,347 | 11,519 | 9,325 | 14,316 |